Kodura Magdalena Anna, Souchelnytskyi Serhiy
Neurocentrum, Karolinska University Hospital, R2:04, Solna, SE-17176, Stockholm, Sweden.
Department of Biotechnology, Kungliga Tekniska Högskolan, Stockholm, Sweden.
Cancer Metastasis Rev. 2015 Dec;34(4):611-8. doi: 10.1007/s10555-015-9583-z.
BRMS1 was discovered over a decade ago as a potential tumor suppressor gene. In this review, we summarize the recent findings about the structure of BRMS1, mechanisms of its action and a role of BRMS1 in the cancer progression. As a suppressor of metastasis, BRMS1 has demonstrated a variety of ways to act on the cell functions, such as cell migration, invasiveness, angiogenesis, cell survival, cytoskeleton rearrangements, cell adhesion, and immune recognition. This variety of effects is a likely reason behind the robustness of anti-metastatic influence of BRMS1. Intracellular signaling mechanisms employed by BRMS1 include regulation of transcription, EGF/HER2 signaling, and expression of NF-kB, fascin, osteopontin, and IL-6. Recently reported clinical studies confirm that BRMS1 can indeed be used as a prognostic marker. Approaches to employ BRMS1 in a development of anti-cancer treatment have also been made. The studies reviewed here with respect to BRMS1 structure, cellular effects, intracellular signaling, and clinical value consolidate the importance of BRMS1 in the development of metastasis.
BRMS1在十多年前被发现是一种潜在的肿瘤抑制基因。在本综述中，我们总结了关于BRMS1结构、其作用机制以及BRMS1在癌症进展中的作用的最新研究结果。作为一种转移抑制因子，BRMS1已证明有多种作用于细胞功能的方式，如细胞迁移、侵袭性、血管生成、细胞存活、细胞骨架重排、细胞黏附和免疫识别。这种多种效应可能是BRMS1抗转移影响稳健性的背后原因。BRMS1采用的细胞内信号传导机制包括转录调控、EGF/HER2信号传导以及NF-κB、肌动蛋白、骨桥蛋白和IL-6的表达。最近报道的临床研究证实BRMS1确实可作为一种预后标志物。在抗癌治疗开发中应用BRMS1的方法也已取得进展。这里综述的关于BRMS1结构、细胞效应、细胞内信号传导和临床价值的研究巩固了BRMS1在转移发展中的重要性。
